Drug intelligence / Profile preview

LB03

Development stage: Preclinical
Lead developer: Link Biologics
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

LB03 is a bivalent DNA aptamer therapeutic candidate under development by LinkBio for the treatment of acute venous thromboembolism (VTE). The drug functions by inhibiting specific protein-protein interactions (PPI) critical to the thrombotic process. By utilizing a bivalent architecture, LB03 aims to achieve higher binding affinity and improved inhibitory activity compared to traditional monovalent aptamers. As of 2024, the program is in the preclinical stage, progressing through early non-clinical studies.

Beyond the preview

Go deeper on LB03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LB03.

Explore the full profile